Feature | Pharmaceuticals | February 24, 2020

FDA Clears Bempedoic Acid Non-statin LDL-cholesterol Lowering Drug

Nexletol lowers LDL-cholesterol with a first-in-class mechanism 

The U.S. Food and Drug Administration (FDA) approved Esperion's bempedoic acid (Nexletor) tablet, an oral, once-daily, non-statin low-density lipoprotein cholesterol (LDL-C) lowering medicine. The drug is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C. 

February 24, 2020 — The U.S. Food and Drug Administration (FDA) approved Esperion's bempedoic acid (Nexletor) tablet, an oral, once-daily, non-statin low-density lipoprotein cholesterol (LDL-C) lowering medicine. The drug is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C. 

The effect of bempedoic acid on cardiovascular morbidity and mortality has not been determined. The agent is the first oral, once-daily, non-statin LDL-C lowering medicine approved since 2002 for indicated patients.

Bempedoic acid is a first-in-class ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C by inhibition of cholesterol synthesis in the liver.

“The FDA approval of Nexletor provides an important option for patients living with elevated LDL-C and ASCVD or increased risk for cardiovascular disease because of HeFH,” said Christie M. Ballantyne, M.D., chairman of Esperion’s Phase 3 Executive Committee and professor and chief of cardiology at Baylor College of Medicine in Houston. “There are millions of patients who are unable to reach their LDL-C targets despite available medicines. Nexletor is the first oral, once-daily, non-statin treatment option for indicated patients in nearly two decades.”

 

FDA Approval of Nexletor Based Two Clinical Studies

The approval of bempedoic acid is supported by a global pivotal Phase 3 LDL-C lowering program conducted in more than 3,000 patients. In these studies, Nexletor provided an average of 18 percent placebo corrected LDL-C lowering when used with moderate or high intensity statins. Results from the Phase 3 development program have been published in The New England Journal of Medicine[1]and The Journal of the American Medical Association.[2]

Nexletor is a first-in-class ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Completed Phase 3 studies conducted in more than 3,000 patients, with over 2,000 patients treated with Nexletor, demonstrated an average 18 percent placebo corrected LDL-C lowering when used in patients on moderate or high-intensity statins. The pharmaceutical is the first oral, once-daily, non-statin LDL-C lowering medicine approved in the U.S. in nearly 20 years for patients with ASCVD or HeFH.

Bempedoic acid was generally well-tolerated in clinical studies. Label warnings and precautions include hyperuricemia, with the development of gout in a small percentage of patients, as well as increased risk of tendon rupture or injury. Overall in Phase 3 studies, the adverse events reported most frequently in patients who received Nexletor were generally reported at similar rates in patients who received placebo. The most common adverse events reported with Nexletor (incidence ≥ 2% and greater than placebo) were upper respiratory tract infections, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, and elevated liver enzymes. The majority of adverse events reported with Nexletor were mild to moderate in severity and balanced in occurrence with adverse events in patients receiving placebo. 

For additional information, please see full prescribing information at Esperion.com.

Nexletor Will be Launched in U.S. Market in Spring 2020

Esperion said it plans to launch Nexletor commercially in the U.S. March 30, 2020.

Esperion said it is working with health insurance providers to help ensure broad insurance coverage and patient access to Nexletor. Eligible patients with commercial drug insurance coverage for the new agent may pay as little as $10 per fill, up to a three-month supply, the company said. Additionally, Esperion said it is committed to achieving the lowest branded tier coverage for Medicare patients. Esperion will provide resources to patients whose physician recommends treatment with Nexletor. These resources include educational materials, a dedicated call center, as well as a co-pay program for eligible patients.

Esperion’s second LDL-C lowering medicine, the bempedoic acid/ezetimibe combination tablet, is currently under review by the U.S. FDA.

Bempedoic acid is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The effect of bempedoic acid on cardiovascular morbidity and mortality has not been determined.

 

CLEAR Cardiovascular Outcomes Trial Evaluating Bempedoic Acid

The effect of bempedoic acid on cardiovascular morbidity and mortality has not been determined. Esperion initiated a global cardiovascular outcomes trial (CVOT) to assess the effects of bempedoic acid on the occurrence of major cardiovascular events in patients with, or at high risk for, cardiovascular disease (CVD) who are only able to tolerate less than the lowest approved daily starting dose of a statin and are considered "statin averse." The CLEAR Cardiovascular Outcomes Trial is an event-driven, global, randomized, double-blind, placebo-controlled study that completed enrollment in August 2019 of 14,032 patients with hypercholesterolemia and high CVD risk at over 1,400 sites in 32 countries.

What is LDL Cholesterol?

Low-density lipoprotein cholesterol (LDL-C) is a waxy, fat-like substance that’s found in the body. Elevated LDL-C contributes to a buildup of this fat in the arteries and can lead to cardiovascular events including heart attack and stroke. Despite standard of care treatments, including statin therapy, it is estimated nearly 15 million patients (approximately one in four patients) in the U.S. cannot achieve guideline recommended LDL-C levels.

References:

1. Ray KK, Bays HE, Catapano AL, et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med. 2019 Mar 14;380(11):1022-1032. doi: 10.1056/NEJMoa1803917.

2. Ulrich Laufs, Maciej Banach, G. B. John Mancini, et al. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance. J Am Heart Assoc. 2019;8:e011662. DOI: 10.1161/JAHA.118.011662.

 

Related Content

News | Pharmaceuticals

May 24, 2022 — Amarin Corporation plc announced that research on the potential population health impact and cost ...

Home May 24, 2022
Home
News | Pharmaceuticals

May 24, 2022 — The U.S. Food and Drug Administration (FDA) has issued a statement that Teva Pharmaceuticals USA has ...

Home May 24, 2022
Home
News | Pharmaceuticals

May 17, 2022 — Amarin Corporation plc announced that research on the potential population health impact and cost ...

Home May 17, 2022
Home
News | Pharmaceuticals

May 13, 2022 — Bristol Myers Squibb’s mavacamten will stand rather unchallenged in the hypertrophic cardiomyopathy (HCM) ...

Home May 13, 2022
Home
News | Pharmaceuticals

April 29, 2022 — Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved Camzyos ...

Home April 29, 2022
Home
News | Pharmaceuticals
March 31, 2022 – Windtree Therapeutics, a biotechnology company focused on advancing multiple late-stage interventions ...
Home March 31, 2022
Home
News | Pharmaceuticals
March 22, 2022 – Fresenius Kabi, a global health care company that specializes in medicines and technologies for ...
Home March 22, 2022
Home
News | Pharmaceuticals

January 5, 2022 — The Feinstein Institutes for Medical Research, the science arm of Northwell Health, recently received ...

Home January 05, 2022
Home
News | Pharmaceuticals

January 4, 2022 — The U.S. Food and Drug Administration (FDA) has cleared Novartis' inclisiran (Leqvio), the first small ...

Home January 04, 2022
Home
News | Pharmaceuticals

December 16, 2021 – Spanish pharmaceutical company Ferrer and the Spanish National Center for Cardiovascular Research ...

Home December 16, 2021
Home
Subscribe Now